Related Experiment Video
Updated: Nov 12, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.5K
Treatment for systemic sclerosis-associated interstitial lung disease.
David Roofeh1, Alain Lescoat1,2,3, Dinesh Khanna1
1Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Current Opinion in Rheumatology
|March 20, 2021
Summary
Current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) are reviewed, highlighting antifibrotic agents like nintedanib and tocilizumab for lung function preservation. Patient stratification guides optimal management strategies for this complex condition.
Area of Science:
- Pulmonology
- Rheumatology
- Pharmacology
Background:
- Systemic sclerosis-interstitial lung disease (SSc-ILD) is a significant cause of morbidity and mortality.
- Effective management strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To review current treatments for SSc-ILD.
- To propose a conceptual framework for disease management.
- To provide case scenarios for clinical guidance.
Main Methods:
- Literature review of current SSc-ILD treatments.
- Analysis of treatment categories including cytotoxic therapies, biologics, antifibrotics, and transplantation.
- Evaluation of recent clinical trial data for nintedanib and tocilizumab.
Main Results:
- Nintedanib demonstrated efficacy in retarding lung function decline in SSc-ILD patients.
- Tocilizumab showed lung function preservation in early SSc with ILD and elevated acute-phase reactants.
- Treatment selection depends on SSc-ILD severity, progression, and patient comorbidities.
Conclusions:
- Stratifying SSc-ILD patients by key characteristics aids in treatment decisions.
- A structured approach to SSc-ILD management is proposed.
- Emerging therapies offer new options for lung function preservation.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
532
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
532
01:24Cystic Fibrosis: Management
307
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
307
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
280
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
280
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
316
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
316
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K